Literature DB >> 11331871

Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus.

S Llanos1, P A Clark, J Rowe, G Peters.   

Abstract

The alternative product of the human INK4a/ARF locus, p14ARF, has the potential to act as a tumour suppressor by binding to and inhibiting the p53 antagonist MDM2. Current models propose that ARF function depends on its ability to sequester MDM2 in the nucleolus. Here we describe situations in which stabilization of MDM2 and p53 occur without relocalization of endogenous MDM2 from the nucleoplasm. Conversely, forms of ARF that do not accumulate in the nucleolus retain the capacity to stabilize MDM2 and p53. We therefore propose that nucleolar localization is not essential for ARF function but may enhance the availability of ARF to inhibit MDM2.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11331871     DOI: 10.1038/35074506

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.824


  79 in total

1.  Differential regulation of E2F1, DP1, and the E2F1/DP1 complex by ARF.

Authors:  Abhishek Datta; Alo Nag; Pradip Raychaudhuri
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

2.  Alternative reading frame protein (ARF)-independent function of CARF (collaborator of ARF) involves its interactions with p53: evidence for a novel p53-activation pathway and its negative feedback control.

Authors:  Md Kamrul Hasan; Tomoko Yaguchi; Yasumasu Minoda; Takashi Hirano; Kazunari Taira; Renu Wadhwa; Sunil C Kaul
Journal:  Biochem J       Date:  2004-06-15       Impact factor: 3.857

3.  Dynamic sorting of nuclear components into distinct nucleolar caps during transcriptional inhibition.

Authors:  Yaron Shav-Tal; Janna Blechman; Xavier Darzacq; Cristina Montagna; Billy T Dye; James G Patton; Robert H Singer; Dov Zipori
Journal:  Mol Biol Cell       Date:  2005-03-09       Impact factor: 4.138

4.  ARF directly binds DP1: interaction with DP1 coincides with the G1 arrest function of ARF.

Authors:  Abhishek Datta; Jayita Sen; Jussara Hagen; Chandrashekhar K Korgaonkar; Michael Caffrey; Dawn E Quelle; Douglas E Hughes; Timothy J Ackerson; Robert H Costa; Pradip Raychaudhuri
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

5.  Intrinsically unstructured domains of Arf and Hdm2 form bimolecular oligomeric structures in vitro and in vivo.

Authors:  Sivashankar G Sivakolundu; Amanda Nourse; Simon Moshiach; Brian Bothner; Chimere Ashley; John Satumba; Jill Lahti; Richard W Kriwacki
Journal:  J Mol Biol       Date:  2008-09-16       Impact factor: 5.469

6.  CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations.

Authors:  Robert R McWilliams; Eric D Wieben; Kari G Chaffee; Samuel O Antwi; Leon Raskin; Olufunmilayo I Olopade; Donghui Li; W Edward Highsmith; Gerardo Colon-Otero; Lauren G Khanna; Jennifer B Permuth; Janet E Olson; Harold Frucht; Jeanine Genkinger; Wei Zheng; William J Blot; Lang Wu; Luciana L Almada; Martin E Fernandez-Zapico; Hugues Sicotte; Katrina S Pedersen; Gloria M Petersen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-07-23       Impact factor: 4.254

7.  ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway.

Authors:  Suzanne N Brady; Yue Yu; Leonard B Maggi; Jason D Weber
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

8.  Role for PP2A in ARF signaling to p53.

Authors:  Madeleine G Moule; Crista H Collins; Frank McCormick; Mike Fried
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

Review 9.  Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.

Authors:  Tiffany Devine; Mu-Shui Dai
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  Disruption of chromosome 11 in canine fibrosarcomas highlights an unusual variability of CDKN2B in dogs.

Authors:  Jesús Aguirre-Hernández; Bruce S Milne; Chris Queen; Patricia C M O'Brien; Tess Hoather; Sean Haugland; Malcolm A Ferguson-Smith; Jane M Dobson; David R Sargan
Journal:  BMC Vet Res       Date:  2009-07-31       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.